What is Radiation Injury Drugs Market Scope?
Radiation injury is defined as the damage to tissues from exposure to ionizing radiation. The ionizing radiation given in large doses can cause acute illness, which leads to a decrease in the production of blood cells and damages the GI tract. It also causes damage to the heart, blood vessels, brain, and especially the skin. The radiation injury can lead to decreased sperm and egg production in both men and women. The high prevalence of cancer patients worldwide and the decision to use radiation therapy are driving the growth of the market for drugs against radiation damage. For example, the International Agency for Research on Cancer reported that in 2020 there will be 19.3 million cancer cases worldwide and 10 million will have died from cancer. Therefore, an increase in cancer patients may fuel the growth of the radiation treatment drug market. Raising reimbursement policies related to radiation therapies and how to manage their side effects can fuel the growth of the radiation therapy drug market. However, a lack of patient awareness of the side effects of radiation therapy can hinder the growth of the radiation damage drug market. New radiation therapies to treat cancer with fewer side effects may hinder the growth of the radiation damage drug market.
The Radiation Injury Drugs market study is being classified by Type (Aerosurf, BMX-001, C-2E2, C-2E5, Des-Asp Angiotensin 1, DG-3 and Others), by Application (Solar and Cosmic Radiation, Man-Made Radiation [Computed Tomography, Cardiac Nuclear Medicine Scans, X-Ray] and Others) and major geographies with country level break-up.
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analysts at AMA predicts that Players from United States will contribute to the maximum growth of Global Radiation Injury Drugs market throughout the predicted period.
FirstString Research Inc. (United States), Pharmain Corp (United States), Synedgen Inc. (United States), Tonix Pharmaceuticals Holding Corp (United States), Windtree Therapeutics Inc. (United States), Merck Sharp & Dohme Corp. (Merck & Co., Inc.) (United States), AstraZeneca (United Kingdom), Pfizer, Inc. (United States), Novartis AG (Switzerland), Eli Lilly and Company (United States), F. Hoffmann-La Roche Ltd. (Switzerland) and Teva Pharmaceutical Industries Ltd. (Israel) are some of the key players profiled in the study.
Analyst at AMA have segmented the market study of Global Radiation Injury Drugs market by Type, Application and Region.
On the basis of geography, the market of Radiation Injury Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
Influencing Market Trend
- Increase in Reimbursement Policies Related To the Radiation Therapies
- The High Prevalence of Cancer Patients Worldwide
- Increased the Healthcare Expenditure
- New Radiation Therapies for the Treatment of Cancer with Less Side-Effect
- Lack of Awareness among the Patients Related To Side-Effects of Radiation
Key Target AudienceNew Entrants/Investors, Analysts and Strategic Business Planners, Manufacturers of Radiation Injury Drugs, Suppliers and Distributors of Radiation Injury Drugs, Venture Capitalists and Private Equity Firms and End-Use Industry
Customization available in this Study:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research features not just specific market sizing estimates, but also include significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets , To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.
Frequently Asked Questions (FAQ):
1. At what growth rate would the Radiation Injury Drugs market expands?
The Global Radiation Injury Drugs market is expected to see a growth of % during projected year 2020 to 2026.
2. Who are the prominent players of the Global Radiation Injury Drugs market?
The prominent players of Global Radiation Injury Drugs market are FirstString Research Inc. (United States), Pharmain Corp (United States), Synedgen Inc. (United States), Tonix Pharmaceuticals Holding Corp (United States), Windtree Therapeutics Inc. (United States), Merck Sharp & Dohme Corp. (Merck & Co., Inc.) (United States), AstraZeneca (United Kingdom), Pfizer, Inc. (United States), Novartis AG (Switzerland), Eli Lilly and Company (United States), F. Hoffmann-La Roche Ltd. (Switzerland) and Teva Pharmaceutical Industries Ltd. (Israel), to name a few.
3. What are the top priorities to focus for Radiation Injury Drugs marketís growth?
In this highly competitive & fast evolving Radiation Injury Drugs industry, the top strategic priorities would remain consistent like innovation, R&D and M&A.